CYTK (Cytokinetics, Incorporated) Stock Financials & Earnings | Market Cap Arena

CYTK (Cytokinetics, Incorporated) Stock Financials & Earnings | Market Cap Arena

CYTKCytokinetics, Incorporated

Mkt Cap$8B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$88M

Net Income (TTM)-$785M

EPS (TTM)-$6.53

Free Cash Flow (TTM)-$535M

Gross Margin-22.3%

Op. Margin-695.4%

Net Margin-891.6%

FCF Margin-607.5%

P/S Ratio (TTM)89.5x

P/E Ratio (TTM)—

YoY Rev Growth+376.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$5M	-$75M	-$124M
Q2 23	$867K	-$82M	-$122M
Q3 23	$378K	-$82M	-$122M
Q4 23	$2M	-$83M	-$127M
Q1 24	$835K	-$81M	-$126M
Q2 24	$249K	-$79M	-$130M
Q3 24	$463K	-$84M	-$141M
Q4 24	$17M	-$77M	-$139M
Q1 25	$2M	-$98M	-$156M
Q2 25	$67M	$64M	-$112M
Q3 25	$2M	-$743K	-$167M
Q4 25	$18M	$15M	-$178M

Valuation

Quarter	P/S	P/E
Q1 23	80.4x	—
Q2 23	791.9x	—
Q3 23	1008.5x	—
Q4 23	1046.6x	—
Q1 24	2100.5x	—
Q2 24	2514.7x	—
Q3 24	2448.3x	—
Q4 24	426.6x	—
Q1 25	410.1x	—
Q2 25	91.9x	—
Q3 25	90.4x	—
Q4 25	89.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$122M	-$123M
Q2 23	-$122M	-$123M
Q3 23	-$96M	-$96M
Q4 23	-$74M	-$74M
Q1 24	-$130M	-$128M
Q2 24	-$99M	-$101M
Q3 24	-$102M	-$104M
Q4 24	-$66M	-$67M
Q1 25	-$132M	-$137M
Q2 25	-$128M	-$132M
Q3 25	-$108M	-$117M
Q4 25	-$143M	-$148M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$402K
Q2 23	$717K
Q3 23	$220K
Q4 23	$77K
Q1 24	$2M
Q2 24	$2M
Q3 24	$2M
Q4 24	$1M
Q1 25	$6M
Q2 25	$4M
Q3 25	$9M
Q4 25	$6M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+301.8%	+63.4%
Q2 23	-99.0%	+23.1%
Q3 23	-85.0%	+10.5%
Q4 23	-14.6%	+0.1%
Q1 24	-81.9%	-1.6%
Q2 24	-71.3%	+6.1%
Q3 24	+22.5%	+15.2%
Q4 24	+912.4%	+20.8%
Q1 25	+89.1%	+23.7%
Q2 25	+26714.9%	+36.7%
Q3 25	+318.1%	+19.4%
Q4 25	+4.9%	+25.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$19M	2153.2%
Q3 23	$19M	4951.3%
Q4 23	$19M	1165.5%
Q1 24	$22M	2588.3%
Q2 24	$25M	9888.4%
Q3 24	$25M	5476.5%
Q4 24	$26M	155.1%
Q1 25	$24M	1491.4%
Q2 25	$28M	41.2%
Q3 25	$31M	1585.5%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$79M	$50M
Q2 23	$83M	$40M
Q3 23	$83M	$40M
Q4 23	$85M	$44M
Q1 24	$82M	$46M
Q2 24	$80M	$51M
Q3 24	$85M	$57M
Q4 24	$94M	$62M
Q1 25	$100M	$57M
Q2 25	$113M	$66M
Q3 25	$99M	$69M
Q4 25	$102M	$92M

Revenue Segments

Quarter	Milestone	Research And Development	Collaboration Revenues
Q1 23	$3M	$2M	—
Q2 23	—	$867K	—
Q3 23	—	$378K	—
Q4 23	$1M	$672K	—
Q1 24	—	$835K	—
Q2 24	—	$249K	—
Q3 24	—	$463K	—
Q3 25	—	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$102M	$562M	$664M
Q2 23	$69M	$497M	$566M
Q3 23	$100M	$440M	$539M
Q4 23	$113M	$502M	$615M
Q1 24	$120M	$499M	$619M
Q2 24	$191M	$867M	$1.1B
Q3 24	$47M	$965M	$1.0B
Q4 24	$95M	$981M	$1.1B
Q1 25	$74M	$865M	$938M
Q2 25	$75M	$783M	$858M
Q3 25	$225M	$737M	$963M
Q4 25	$882M	$0	$882M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	95M	+0.5%
Q2 23	96M	+0.6%
Q3 23	96M	+0.3%
Q4 23	99M	+3.1%
Q1 24	102M	+2.9%
Q2 24	109M	+7.2%
Q3 24	118M	+7.7%
Q4 24	118M	+0.3%
Q1 25	118M	+0.4%
Q2 25	119M	+0.8%
Q3 25	120M	+0.4%
Q4 25	122M	+2.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$510K	92
FY 15	$287K	100
FY 16	$838K	127
FY 17	$98K	137
FY 18	$242K	130
FY 19	$172K	156
FY 20	$303K	184
FY 21	$278K	253
FY 22	$231K	409
FY 23	$18K	423
FY 24	$37K	498
FY 25	$25K	4K